The CEO and MD of Foresite Capital, Jim Tananbaum received the announcement of Dr. Molly He as a new venture partner of Foresite Capital with a lot of positivity. According to the Managing Director, Dr. He brings with her a lot of knowledge and experience that will propel the firm to the next level. Her experience of a decade and a half in genomic research and pharmaceuticals is something that is going to add more value to the company.
Jim recognizes that Dr. He is one of the most respected scientists in the next generation sequencing which is why it is an honor to welcome her to the team. Her extensive expertise in genomics and drug development coupled with a near perfect record of accomplishment in leadership is something that Jim is happy about and willing to explore further. In fact, it is viewed as one of the ways that will expand the company’s portfolio.
Dr. He was responsible for handling the company’s global protein reagent innovations and improvements when she worked at Illumina. Before joining Illumina as the Scientific Research Director, she worked at Pacific Biosciences where her mandate was developing the company’s single molecular real time sequencing chemistry. Before then she had a decade’s experience in the pharmaceutical industry with a focus on the structural design of the antibody and small molecule drugs that target cancer and immune diseases.
According to Biz Journals, Dr. He has a bachelor’s degree in Biochemistry from Nankai University and a PhD in Biophysics from the University of California. She has more than twenty papers published and holds more than 20 patent applications in the field of next-generation sequencing as well as in the field of personalized medicine.
Dr. He herself is excited to be joining Foresite Capital as she recognizes that the company has an outstanding reputation of investing in the best projects in all sectors. She feels that it is an excellent move especially since she will be contributing to the company’s portfolio.
About Jim Tananbaum
Jim Tananbaum formed Foresite Capital in 2011. He also cofounded several other profitable companies such as GelTex and Theravance.
He earned his Bs and BSEE from Yale University in applied mathematics and computer science respectively. Jim has an MS from MIT and an MBA from Harvard. His academic qualifications and excellence have contributed to his successful leadership. For more info visit Speakerpedia.
Follow her on Twitter